Bellerophon Therapeutics

Hampton, United States Founded: 2014 • Age: 12 yrs
Drug-device therapies for pulmonary hypertension are developed.

About Bellerophon Therapeutics

Bellerophon Therapeutics is a company based in Hampton (United States) founded in 2014.. The company has 18 employees as of December 31, 2022. Bellerophon Therapeutics operates in a competitive market with competitors including BTG International, Pulnovo Medical, SoniVie, Aria CV and Adient Medical, among others.

  • Headquarter Hampton, United States
  • Employees 18 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-19.83 M
    -12
    as on Dec 31, 2022
  • EBITDA
    $-22.38 M
    -11
    as on Dec 31, 2022
  • Latest Funding Round
    $23.44 M (USD), Post-IPO

    Oct 09, 2017

  • Investors
    Linde Group

    & 3 more

  • Employee Count
    18

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Bellerophon Therapeutics
Headcount 10-50
Employee Profiles 1
Employee Profiles
People
Manfred Hanuschek
Financial Consultant

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Bellerophon Therapeutics

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $23.4M
  • First Round

    (27 Sep 2017)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2017 Amount Post-IPO - Bellerophon Therapeutics Valuation

investors

Sep, 2017 Amount Post-IPO - Bellerophon Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Bellerophon Therapeutics

Bellerophon Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Linde Group, Puissance Capital and New Mountain Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
New Mountain Capital manages investments in private equity, credit, and net lease strategies.
Founded Year Domain Location
VC & PE firm focused on healthcare sector
Founded Year Domain Location
Manages diversified investment portfolios across multiple asset classes.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Bellerophon Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Bellerophon Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Bellerophon Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Bellerophon Therapeutics

Bellerophon Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BTG International, Pulnovo Medical, SoniVie, Aria CV and Adient Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics are developed for oncology, pulmonology, hematology, and anti-venom treatments.
domain founded_year HQ Location
A medical device for pulmonary hypertension treatment is developed.
domain founded_year HQ Location
A denervation catheter for pulmonary hypertension treatment is developed.
domain founded_year HQ Location
Device for pulmonary hypertension
domain founded_year HQ Location
Bioabsorbable medical devices are developed for pulmonary embolism prevention.
domain founded_year HQ Location
Retrievable vena cava filters are developed to prevent pulmonary emboli.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Bellerophon Therapeutics

Frequently Asked Questions about Bellerophon Therapeutics

When was Bellerophon Therapeutics founded?

Bellerophon Therapeutics was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Bellerophon Therapeutics located?

Bellerophon Therapeutics is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.

How many employees does Bellerophon Therapeutics have?

As of Dec 31, 2022, the latest employee count at Bellerophon Therapeutics is 18.

What does Bellerophon Therapeutics do?

Bellerophon Therapeutics is a clinical-stage biotherapeutics company developing products to treat cardiopulmonary and cardiac diseases. Its product, the INOpulse is a combination drug-device therapy that they are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF). The device delivers Nitrous Oxide, a vasodilator into the pulmonary blood vessels, thus dilating them. The company spun out from Ikaria in 2014. Its key products include a nitric oxide delivery device and a bio-absorbable cardiac matrix. Both products are still in development. The company went public in Feb 2015.

Who are the top competitors of Bellerophon Therapeutics?

Bellerophon Therapeutics's top competitors include Pulnovo Medical, SoniVie and BTG International.

Who are Bellerophon Therapeutics's investors?

Bellerophon Therapeutics has 4 investors. Key investors include Linde Group, Puissance Capital, New Mountain Capital, and Venrock Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available